BLC2001: Phase II Trial of FGFR Inhibitor Erdafitinib in Patients With FGFR-Altered Metastatic or Unresectable Urothelial Carcinoma

June 1-5, 2018; Chicago, Illinois
This trial met its primary endpoint with an ORR of 40% and showed a manageable and well-tolerated safety profile for erdafitinib in FGFR-altered UC.
Format: Microsoft PowerPoint (.ppt)
File Size: 190 KB
Released: June 12, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

A downloadable slideset on new approaches to managing low-grade upper tract urothelial cancer from Clinical Care Options (CCO).

Surena Matin, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

A downloadable slideset from Clinical Care Options (CCO) focused on the latest evidence for managing non-muscle invasive bladder cancer (NMIBC).

Seth P. Lerner, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue